Arrowhead Pharmaceuticals reported a GAAP loss of $18.506 million for 6 months of fiscal year 2022, down 2.5 times from $47.55 million in the previous year. Revenue increased 2.3 times to $179.244 million from $54.113 million a year earlier.

The loss of Arrowhead Pharmaceuticals under GAAP for 3 months of fiscal year 2022 was $62.87 million, a 3-fold increase from $20.732 million in the previous year. Revenue increased 28.8% to $27.439 million from $21.303 million a year earlier.

Arrowhead Pharmaceuticals' GAAP loss for fiscal year 2021 was $140.848 million, up 66.6% from $84.553 million in the prior year. Revenue increased 57.2% to $138.287 million compared to $87.992 million a year earlier.

Arrowhead Pharmaceuticals reported a GAAP loss of $77.474 million for 9 months of fiscal year 2021, up 2.1 times from $36.12 million in the prior year. Revenue increased 24.4% to $100.004 million from $80.359 million a year earlier.